NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare NewAmsterdam Pharma to related companies based on the strength of its earnings, valuation, profitability, analyst recommendations, risk, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of current recommendations for NewAmsterdam Pharma and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
| NewAmsterdam Pharma Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
NewAmsterdam Pharma currently has a consensus price target of $49.82, suggesting a potential upside of 170.60%. As a group, “Biotechnology” companies have a potential upside of 114.63%. Given NewAmsterdam Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than its rivals.
Earnings and Valuation
This table compares NewAmsterdam Pharma and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| NewAmsterdam Pharma | $22.50 million | -$203.82 million | -10.89 |
| NewAmsterdam Pharma Competitors | $688.58 million | $7.69 million | -17.98 |
NewAmsterdam Pharma’s rivals have higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
NewAmsterdam Pharma has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma’s rivals have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.
Profitability
This table compares NewAmsterdam Pharma and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NewAmsterdam Pharma | -789.95% | -31.39% | -28.32% |
| NewAmsterdam Pharma Competitors | -12,224.75% | -204.85% | -31.52% |
Summary
NewAmsterdam Pharma beats its rivals on 10 of the 13 factors compared.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
